Gutbier B, Jiang X, Ehrler C, Mitchell TJ, Weissmann N, Van Slyke P, Dumont DJ, Suttorp N, Witzenrath M. American Thoracic Society 2016 International Conference.
Gutbier B, Jiang X, Ehrler C, Mitchell TJ, Weissmann N, Van Slyke P, Dumont DJ, Suttorp N, Witzenrath M. American Thoracic Society 2016 International Conference.
http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5458
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.